BR112023013790A2 - Proteína de ligação a antígeno dirigida à alfa-toxina de staphylococcus aureus e aplicação da mesma - Google Patents

Proteína de ligação a antígeno dirigida à alfa-toxina de staphylococcus aureus e aplicação da mesma

Info

Publication number
BR112023013790A2
BR112023013790A2 BR112023013790A BR112023013790A BR112023013790A2 BR 112023013790 A2 BR112023013790 A2 BR 112023013790A2 BR 112023013790 A BR112023013790 A BR 112023013790A BR 112023013790 A BR112023013790 A BR 112023013790A BR 112023013790 A2 BR112023013790 A2 BR 112023013790A2
Authority
BR
Brazil
Prior art keywords
staphylococcus aureus
binding protein
toxin
antigen
application
Prior art date
Application number
BR112023013790A
Other languages
English (en)
Portuguese (pt)
Inventor
Bohua Li
Maomao An
Shiyu Guo
Simin Chen
Xiran Qiu
Original Assignee
Starmab Biologics Suzhou Co Ltd
Starshining Biologics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starmab Biologics Suzhou Co Ltd, Starshining Biologics Shanghai Co Ltd filed Critical Starmab Biologics Suzhou Co Ltd
Publication of BR112023013790A2 publication Critical patent/BR112023013790A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112023013790A 2021-01-11 2022-01-11 Proteína de ligação a antígeno dirigida à alfa-toxina de staphylococcus aureus e aplicação da mesma BR112023013790A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110033695 2021-01-11
PCT/CN2022/071382 WO2022148480A1 (zh) 2021-01-11 2022-01-11 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用

Publications (1)

Publication Number Publication Date
BR112023013790A2 true BR112023013790A2 (pt) 2023-10-03

Family

ID=82357142

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023013790A BR112023013790A2 (pt) 2021-01-11 2022-01-11 Proteína de ligação a antígeno dirigida à alfa-toxina de staphylococcus aureus e aplicação da mesma

Country Status (7)

Country Link
US (1) US20240059764A1 (https=)
EP (1) EP4286409A4 (https=)
JP (1) JP2024503425A (https=)
KR (1) KR20230147616A (https=)
CN (1) CN117062908A (https=)
BR (1) BR112023013790A2 (https=)
WO (1) WO2022148480A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410371A1 (en) * 2023-02-03 2024-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies against alpha-hemolysin from staphylococcus aureus
CN118480121B (zh) * 2024-05-13 2025-04-01 重庆原伦生物科技有限公司 一种特异性结合金黄色葡萄球菌蛋白a的抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
WO2013093693A1 (en) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
TWI781130B (zh) * 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2020041394A1 (en) * 2018-08-23 2020-02-27 Trustees Of Tufts College Binding proteins, compositions and methods thereof for neutralization of infection of pathogens having a type iii secretion system
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
CN110577594B (zh) * 2019-08-19 2021-05-14 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a21、应用及试剂盒
CN110526967A (zh) * 2019-08-19 2019-12-03 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a13、应用及试剂盒
CN110526966B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b6、应用及试剂盒
CN110563839A (zh) * 2019-08-19 2019-12-13 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b1、应用及试剂盒
CN110526968B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b7、应用及试剂盒

Also Published As

Publication number Publication date
US20240059764A1 (en) 2024-02-22
KR20230147616A (ko) 2023-10-23
CN117062908A (zh) 2023-11-14
EP4286409A4 (en) 2025-01-01
EP4286409A1 (en) 2023-12-06
WO2022148480A1 (zh) 2022-07-14
JP2024503425A (ja) 2024-01-25

Similar Documents

Publication Publication Date Title
BR112023013790A2 (pt) Proteína de ligação a antígeno dirigida à alfa-toxina de staphylococcus aureus e aplicação da mesma
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
Lanjri et al. In vitro evaluation of the susceptibility of Acinetobacter baumannii isolates to antiseptics and disinfectants: comparison between clinical and environmental isolates
EP3761892C0 (en) SYSTEM FOR DIAGNOSIS AND TREATMENT OF MICROVASCULAR OBSTRUCTIONS
EA201991643A1 (ru) Человеческие антитела к токсину гемолизину а s.aureus
Kampf et al. Insufficient neutralization in testing a chlorhexidine-containing ethanol-based hand rub can result in a false positive efficacy assessment
BR112022013480A2 (pt) Métodos de tratamento de coronavírus
EP3541837A4 (en) HUMANE IGG FC DOMAIN VARIANTS WITH IMPROVED EFFECT FUNCTION
Maksouri et al. Moroccan strains of Leishmania major and Leishmania tropica differentially impact on nitric oxide production by macrophages
EP3791869A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES WITH COX2 ACETYLATING AGENT AS THE ACTIVE SUBSTANCE
BR112022004831A2 (pt) Anticorpos que se ligam a vista em ph ácido
BR112021014406A2 (pt) Derivados de tiazolopiridina como antagonistas de receptor de adenosina
Nahaichuk et al. Correlation of susceptibility to antiseptics with biofilm-forming properties in acinetobacter baumannii as a pathogen of surgical infection
Leitgeb et al. Antibacterial activity of a sterile antimicrobial polyisoprene surgical glove against transient flora following a 2-hours simulated use
EP4438048A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO T LYMPHOCYTES
EP3804728A4 (en) COMPOSITION WITH INOTODIOL COMPOUND AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF ALLERGY DISEASES
Sicher et al. Efficacy of 233 nm LED far UV-C-radiation against clinically relevant bacterial strains in the phase 2/step 2 in vitro test on basis of EN 14561 and on an epidermis cell model
Horváth et al. Natural substances from higher plants as potential anti-MRSA agents
MA54936A (fr) Triamtérène ou nolatrexed destinés à être utilisés dans le traitement de la phénylcétonurie
Ciotti et al. Bacteria which are highly resistant to antibiotics are not resistant hydro-alcoholic products
MA53707A (fr) Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne
EP4340613A4 (en) ANTIMICROBIAL SKIN CARE AND TREATMENT COMPOSITION
EP4302717A4 (en) Medical treatment tool
BR112022000417A2 (pt) Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv
BR112022020865A2 (pt) Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: STARMAB BIOLOGICS (SUZHOU) CO., LTD (CN)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: STARMAB BIOLOGICS (SUZHOU) CO., LTD (CN) ; STARSHINING BIOLOGICS (SHANGHAI) CO., LTD (CN)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2781 DE 24/04/2024 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: STARMAB BIOLOGICS (SUZHOU) CO., LTD (CN) ; STARMAB BIOLOGICS (SHANGHAI) CO., LTD (CN)